Tag
Initiating cholesterol-lowering therapy during childhood in familial hypercholesterolaemia substantially reduces LDL-C burden and cardiovascular risk, highlighting the importance of early diagnosis and treatment.
A cluster RCT in Brazil found that a digitally enabled quality improvement intervention modestly reduced LDL-C and increased treatment intensification in ASCVD patients, but a care gap remained.
Obicetrapib significantly lowers lipoprotein(a), LDL cholesterol, and apolipoprotein B in high cardiovascular risk patients, offering a promising addition to lipid-lowering therapies, especially for patients with mild to moderate Lp(a) elev
A genome-first study found similar rates of pathogenic FH variants in African and European ancestry groups, but uncertain variants were more common and potentially more harmful in African ancestry individuals, highlighting the need for more
A large multi-cohort genome-first study found similar prevalence of pathogenic FH variants across ancestries, but more VUSs and greater LDL-C and myocardial infarction risk among African ancestry individuals, highlighting likely underclassi
A long-term analysis of the FOURIER trials reveals that achieving ultra-low LDL-C levels (<40 mg/dL) significantly reduces recurrent stroke and major cardiovascular events in stroke survivors, without increasing hemorrhagic stroke risk,
A large-scale cohort study from the Western Denmark Heart Registry demonstrates that high LDL-C remains a significant predictor of non-calcified plaque and coronary heart disease events in patients with a CAC score of zero, particularly amo
This secondary analysis of the CONNECT trial demonstrates that achieving guideline-endorsed LDL-C levels significantly lowers the risk of neoatherosclerosis three years post-DES implantation in STEMI patients, underscoring the vital role of
In adults with heterozygous familial hypercholesterolemia on statin therapy, oral enlicitide decanoate reduced LDL‑C by ~58% at 24 weeks versus placebo and was well tolerated through 52 weeks.
The ORION-13 trial demonstrates that inclisiran significantly lowers LDL cholesterol by 33.3% and is safe and well tolerated in adolescents with homozygous familial hypercholesterolemia, addressing an unmet pediatric treatment need.
